A fast and highly efficient microwave accelerated solution phase procedure for the synthesis of a series of 2-phenyl-3-(benzothiazol-2-yl)-4[3H]-quinazolinones, substituted in the benzothiazole ring, is developed. The title compounds were characterized by elemental analyses, IR, 1 H NMR, and EI-MS data. The anticonvulsant activity of all the new compounds (3a-m and 4a-m) was evaluated against Maximum Electroshock (MES) induced seizures and against subcutaneous pentylenetetrazole (PTZ) induced seizures model in mice.The neurotoxicity was assessed using the Rotorod procedure. All the compounds tested were administered intraperitoneally at a various dose levels ranging from 7-200 mg/Kg body weight and the median toxic dose (TD 50 ) and the protection index (PI) values were determined. In general compounds 3a-m were found to be more potent compared to compounds 4a-m. Among the compound tested, the compound 3e in the 2-phenyl-3-(benzothiazole-2-yl)-4[3H]-quinazolinone series and 4l in the 6,8-dibromo-2-phenyl-3-(benzothiazole-2-yl)-4[3H]-quinazolinone series were found to be the most potent.